AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

Astra Zeneca's Breast Cancer Leader Says Community Education is Crucial; Getting The Extraordinary Wave of Innovation To Patients Who Need Hope ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

A woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as 'lumpy boobs' for two years. Lea Hughes, 38, first noticed a small lump on her right breast at the age of ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials.

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

A WIRRAL woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as her having "lumpy boobs" for ...